Sarah Cannon Research Institute to Present Latest Research Insights at the 2023 ASH Annual Meeting & Exposition

December 7, 2023 |

8 min read

Sarah Cannon Research Institute announced that more than 80 abstracts and presentations have been selected for inclusion at the 65th American Society of Hematology Annual Meeting & Exposition.

65+ investigators to present clinical trial data focused on the improvement of blood cancer and blood disorder care

NASHVILLE, Tenn.--(BUSINESS WIRE)-- Sarah Cannon Research Institute (SCRI) announced today that more than 80 abstracts and presentations have been selected for inclusion at the 65^th American Society of Hematology (ASH) Annual Meeting & Exposition. Hosted in San Diego and online from Dec. 9-12, the meeting is the year’s most comprehensive global hematology event.

At this year’s ASH Annual Meeting & Exposition, SCRI investigators, including physicians from The US Oncology Network, will discuss groundbreaking research in malignant and non-malignant blood cancer, CAR T-Cell therapy, real-world outcomes, and targeted immunotherapies.

“We look forward to sharing our research insights, including the latest developments in the treatment of sickle cell disease, immune effector cell therapy, and other novel therapies that are advancing the way we treat blood cancers and blood disorders,” said Howard A. “Skip” Burris, III, MD, President, SCRI. “We are proud to share these important updates through the work of more than 65 investigators from across our network, which can only be done through the power of collaboration.”

In November 2022, McKesson and HCA Healthcare formed a joint venture combining SCRI with former US Oncology Research, the research arm of The US Oncology Network. The collaboration brings together physicians who are actively enrolling patients into clinical trials at more than 250 locations in 24 states across the U.S. More than 65 investigators from the joint venture will present insights at this year’s Annual Meeting. Separately, Ontada, McKesson’s oncology real-world data and evidence, clinical education, and provider technology business, is also presenting two posters at the conference.

Featured presentations include:

Haydar Frangoul, MD, MS, Sarah Cannon Pediatric Hematology/Oncology & Cellular Therapy Program at TriStar Centennial Medical Center, is first author on an oral presentation titled, “Exagamglogene Autotemcel for Severe Sickle Cell Disease” to be shared on Monday, December 11 at 4:30 p.m. (presentation time 4:45 p.m.) PST.

This presentation will include important updates from CLIMB SCD-121, an ongoing, 24-month, phase 3 trial of exa-cel in patients age 12-35 with sickle cell disease.

Dr. Frangoul is also co-author on an oral presentation titled, “Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia” to be shared on Monday, December 11 at 4:30 p.m. (presentation time 5:00 p.m.) PST.

____________________________________________________________________________

Chris Yasenchak, MD, Willamette Valley Cancer Institute and Research Center, Jason Melear, MD, Texas Oncology, John M. Burke, MD, Rocky Mountain Cancer Centers, Habte A. Yimer, MD, Texas Oncology, Mihir Raval, MD, New York Oncology Hematology, Miguel Islas-Ohlmayer, MD, St. Elizabeth Healthcare, Mitul Gandhi, MD, Virginia Cancer Specialists, and John Scott Renshaw, MD, Texas Oncology, are co-authors on the oral presentation, “Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced Stage Classical Hodgkin Lymphoma: Efficacy and Safety Results from the Single Arm Phase 2 Study” presented on Sunday, December 10 at 4:30 p.m. (presentation time 4:45 p.m.) PST.

John M. Burke, MD, Rocky Mountain Cancer Centers, Mitul Gandhi, MD, Virginia Cancer Specialists, and Christopher A. Yasenchak, MD, Willamette Valley Cancer Institute and Research Center, will highlight “Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early-Stage Classical Hodgkin Lymphoma (SGN35-027 Part C)” through an oral presentation on Sunday, December 10 at 4:30 p.m. (presentation time 5:30 p.m.) PST.

These studies represent two arms of significant clinical trials exploring treatment advancements in classical Hodgkin Lymphoma (both advanced and early stage).

____________________________________________________________________________

Tonya Cox, BSN, Sarah Cannon Transplant & Cellular Therapy Network, is first author alongside seventeen SCRI/Sarah Cannon Transplant & Cellular Therapy Network co-authors on an oral presentation titled, “Standardization of Outpatient Care after CAR-T Therapy Across a Large Cell Therapy Network- Through Technology and Decentralized Virtual Nurses: Preliminary Results” which will be presented on Saturday, December 9 at 2:00 p.m. PST.

This study describes the innovative care model of using remote patient monitoring to provide chimeric antigen receptor T-cell therapies in the outpatient setting across a network of cell therapy centers.

____________________________________________________________________________

Jeffrey Matous, MD, Colorado Blood Cancer Institute, is first author on an oral presentation titled, “Talquetamab + Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Safety and Preliminary Efficacy Results from the Phase 1b MonumenTAL-2 Study” which will be shared on Monday, December 11 at 4:30 p.m. PST.

This presentation will offer an update out of a Phase I study for patients with relapsed/refractory multiple myeloma.

____________________________________________________________________________

Paul Shaughnessy, MD, Sarah Cannon Transplant & Cellular Therapy Program at Methodist Hospital, is a co-author on a late-breaking oral presentation, titled, “Reduced Intensity Haploidentical Bone Marrow Transplantation in Adults with Severe Sickle Cell Disease: BMT CTN 1507" which will be presented on Tuesday, December 12 at 9:00 a.m. PST.

This presentation presents the results of a Phase II multi-center single-arm prospective clinical trial of haploidentical transplantation in adults with severe sickle cell disease.

____________________________________________________________________________

A full list of presentations can be found here. Investigators highlighting research at this year’s ASH Annual Meeting & Exposition represent studies being conducted across SCRI, Sarah Cannon Transplant & Cellular Therapy Network, and partners from The US Oncology Network and Ontada.

About Sarah Cannon Research Institute

Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. In 2022, SCRI formed a joint venture with former US Oncology Research to expand clinical trial access across the country. It has conducted more than 700 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA today. SCRI’s research network brings together more than 1,300 physicians who are actively enrolling patients into clinical trials at more than 250 locations in 24 states across the U.S. Learn more about our research offerings.

About The Sarah Cannon Transplant & Cellular Therapy Network

The Sarah Cannon Transplant & Cellular Therapy Network offers adult and pediatric patients convenient and community-based access to treatments for blood cancer and blood and immune-related disorders, including hematopoietic cell transplantation and cellular therapy. Our Network of ten FACT/JACIE accredited transplant centers across the United States and United Kingdom treats more than 1,600 transplant and cellular therapy patients and 2,000 acute leukemia patient admissions annually. Emphasis is placed on providing high-quality research-based care with the opportunity for patients to enroll on innovative clinical trials. For more information about the Sarah Cannon Transplant & Cellular Therapy Network, visit sarahcannon.com.

About McKesson Oncology and Specialty Solutions

It’s an unprecedented time for patients living with cancer as life sciences companies race to create new, cutting-edge therapies. With cancer care becoming more targeted, providers, life sciences companies, and payers face a multitude of challenges and complexity in the development of new treatments and making them accessible to patients in need. At McKesson, our unmatched portfolio of oncology businesses and partners provide research, insights, technologies, and services that are helping to address these hurdles and improve cancer and specialty care.

McKesson is fueling discovery by helping patients participate in cutting-edge clinical trials closer to home through the joint venture between US Oncology Research and Sarah Cannon Research Institute.
The US Oncology Network and McKesson Provider Solutions are advancing specialty care and high-quality cancer care in the communities where patients live by supporting the practices of thousands of independent, community-based providers.
Ontada^®, a McKesson business dedicated to oncology, generates real-world data (RWD) and real-world evidence (RWE) and provides clinical education and provider technology to inform and improve cancer care.
As one of the largest distributors of oncology and specialty medicines, we are ensuring medicines make their way to those who are counting on them.
And through CoverMyMeds, Biologics by McKesson, and GPO services, our work continues to help patients access, afford, and adhere to their medicines.